Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.62 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.47 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 8/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.43 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | CCKAR | P32238 | 1/20 | 0.40 |
| ▸ | CCKBR | P32239 | 1/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.40 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL949512 | 1.00 | EPHX2 (0.62) | EPHX2GAAMAPK10RIPK1IDO1 | |
| SCHEMBL645858 | 1.00 | EPHX2 (0.62) | EPHX2GAAMAPK10RIPK1IDO1 | |
| SCHEMBL18419861 | 0.88 | EPHX2 (0.48) | EPHX2RIPK1NAAA | |
| SCHEMBL6176701 | 0.85 | EPHX2 (0.51) | EPHX2GAARIPK1IDO1NAAA | |
| SCHEMBL15811245 | 0.85 | EPHX2 (0.51) | EPHX2GAAMAPK10RIPK1NAAA | |
| SCHEMBL8210416 | 0.84 | EPHX2 (0.47) | EPHX2GAARIPK1IDO1NAAA | |
| SCHEMBL31656028 | 0.84 | EPHX2 (0.47) | EPHX2GAARIPK1NAAANFKB1 | |
| SCHEMBL6177311 | 0.84 | EPHX2 (0.47) | EPHX2GAARIPK1IDO1NAAA | |
| SCHEMBL30832132 | 0.84 | EPHX2 (0.47) | EPHX2GAARIPK1NAAANFKB1 | |
| SCHEMBL10263516 | 0.84 | EPHX2 (0.50) | EPHX2GAAMAPK10IDO1NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12485179-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2025-12-02 | — | — | US | disclosed |
| US-20220273803-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2022-09-01 | — | — | US | disclosed |
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2022-05-31 | — | — | US | disclosed |
| US-20200384114-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2020-12-10 | — | — | US | disclosed |
| US-20200384114-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | PURDUE RESEARCH FOUNDATION | 2020-12-10 | — | — | US | disclosed |
| US-10786580-B2 | Cholecystokinin 2 receptor targeted NIR imaging and use thereof | On Target Laboratories, LLC (US) | 2020-09-29 | — | — | US | disclosed |
| US-10765756-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2020-09-08 | — | — | US | disclosed |
| US-10765756-B2 | Cholecystokinin B receptor targeting for imaging and therapy | PURDUE RESEARCH FOUNDATION (US) | 2020-09-08 | — | — | US | disclosed |
| US-10500286-B2 | CCK2R-drug conjugates | ENDOCYTE, INC. (US) | 2019-12-10 | — | — | US | disclosed |
| EP-0945445-B9 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2005-12-28 | — | — | EP | disclosed |
| EP-1234818-B1 | CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME | ZERIA PHARM CO LTD (JP) | 2004-09-08 | — | — | EP | disclosed |
| US-6747022-B2 | TREATING DIGESTIVE TRACT DISEASE RESULTING FROM EXCESSIVE SECRETION OF GASTRIC ACID | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2004-06-08 | — | — | US | disclosed |
| EP-0945445-B1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARM CO LTD (JP) | 2003-09-03 | — | — | EP | disclosed |
| US-20030096809-A1 | Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2003-05-22 | — | — | US | disclosed |
| EP-1234818-A1 | CALCIUM SALTS OF 1,5-BENZODIAZEPINE DERIVATIVES, PROCESS FOR PRODUCING THE SALTS AND DRUGS CONTAINING THE SAME | Zeria Pharmaceutical Co., Ltd. (JP) | 2002-08-28 | — | — | EP | disclosed |
| US-6344452-B1 | GASTRIN RECEPTOR ANTAGONIST, GASTROINTESTINAL DISORDERS, ETC | ZERIA PHARMACEUTICALS CO., LTD. (JP) | 2002-02-05 | — | — | US | disclosed |
| US-6239131-B1 | WHICH HAVE GASTRIN AND/OR CCK-B (CHOLECYSTOKININ-B) RECEPTOR ANTAGONISM, USEFUL AS REMEDIES FOR GASTRIC ULCER AND GASTROINTESTINAL MOVEMENT DISORDER. | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 2001-05-29 | — | — | US | disclosed |
| EP-1085014-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | Zeria Pharmaceutical Co., Ltd. (JP) | 2001-03-21 | — | — | EP | disclosed |
| EP-0945445-A1 | 1,5-BENZODIAZEPINE DERIVATIVES | ZERIA PHARMACEUTICAL CO., LTD. (JP) | 1999-09-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11344623-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | EPHX2 2332/4885GAA 2876/4885MAPK10 2069/4885 |
| US-10765756-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | EPHX2 2332/4885GAA 2876/4885MAPK10 2069/4885 |
| US-10786580-B2 | Cholecystokinin 2 receptor targeted NIR imaging and use thereof | CCKAR, CCKBR, GRPR | EPHX2 2903/4885GAA 3666/4885MAPK10 2890/4885 |
| US-20200384114-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | EPHX2 2332/4885GAA 2876/4885MAPK10 2069/4885 |
| US-20030096809-A1 | Calcium salts of 1,5-benzodiazepine derivatives, process for producing the salts and drugs containing the same | CCKBR, CCKAR, GABRB1 | EPHX2 2897/4885GAA 1647/4885MAPK10 965/4885 |
| US-12485179-B2 | Cholecystokinin B receptor targeting for imaging and therapy | CCKBR, CCKAR, GRPR | EPHX2 2332/4885GAA 2876/4885MAPK10 2069/4885 |
| US-10500286-B2 | CCK2R-drug conjugates | CCKAR, CCKBR, GIPR | EPHX2 2387/4885GAA 1269/4885MAPK10 1705/4885 |
| US-20220273803-A1 | CHOLECYSTOKININ B RECEPTOR TARGETING FOR IMAGING AND THERAPY | CCKBR, CCKAR, GRPR | EPHX2 2332/4885GAA 2876/4885MAPK10 2069/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.